Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
Authors: Z Einbeigi, D Bergström, T Hatschek and M Malmberg
Publication Date: 25 Sep 2008
Clinical Medicine: Oncology 2008:2 533-538
Z. Einbeigi1, D. Bergström2, T. Hatschek3 and M. Malmberg4
1Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden. 2Roche AB, Stockholm, Sweden. 3Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden. 4Department of Oncology, Helsingborg Hospital, Helsingborg, Sweden.
Abstract
Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m2, paclitaxel 155 mg/m2 (both day 1) and capecitabine 665 mg/m2 twice daily (days 1–14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.
Keywords: epirubicin; paclitaxel; capecitabine, first-line chemotherapy, metastatic breast cancer, phase I/II
Download this full text open access article
Send to Endnote
(252.16 KB PDF format)
Readers of this also read:
- Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
- Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma – A Critical Review
- Pre-operative Concomitant Radio-chemotherapy in Bulky Carcinoma of the Cervix: A Single Institution Study
- MCAM: A Database to Accelerate the Identification of Functional Cell Adhesion Molecules
